Lisa A. Raedler, PhD, RPh

Medical Writer
Medical Writer
Authored Items
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh
Web Exclusives in Select Drug Profiles
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh
Web Exclusives in Select Drug Profiles
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh
Web Exclusives in Select Drug Profiles
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh
Web Exclusives in Select Drug Profiles
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh
Web Exclusives in Select Drug Profiles
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Eylea (Aflibercept) Receives FDA Approval of New Dose for Age-Related Macular Degeneration
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation
Lisa A. Raedler, PhD, RPh
March 2019, Vol 12, Tenth Annual Payers' Guide in Payers' Guide, Select Drug Profiles
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Lung Cancer, Select Drug Profiles, Payers' Guide
Aliqopa (Copanlisib), an Intravenous PI3K Inhibitor, Approved for Patients with Relapsed Follicular Lymphoma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Revlimid (Lenalidomide) First Drug Approved for Post-Transplant Maintenance Therapy in Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Darzalex (Daratumumab) Approved as Part of a 3-Drug Regimen for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
March 2017, Vol 10, Eighth Annual Payers' Guide in Select Drug Profiles, Payers' Guide
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
ProAir RespiClick (Albuterol Sulfate): First Breath-Actuated Inhaler Approved for the Treatment or Prevention of Bronchospasm
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Opdivo (Nivolumab), a PD-1 Inhibitor, Receives New Indications for Melanoma, NSCLC, and Renal-Cell Carcinoma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Cyramza (Ramucirumab) Receives New FDA Indication for Second-Line Treatment of Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor Approved for Postmenopausal Women with Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Payers' Guide
Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Lisa A. Raedler, PhD, RPh
March 2016, Vol 9, Seventh Annual Payers' Guide in Drug Updates, FDA Approvals, Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Web Exclusives in Drug Updates
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Lisa A. Raedler, PhD, RPh
March 2015, Vol 8, Sixth Annual Payers' Guide in Drug Updates, Payers' Guide
Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea
Lisa A. Raedler, PhD, RPh
Payer Perspectives in Dermatology in Payers' Perspectives
Abraxane (nab-Paclitaxel) Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Anoro Ellipta (Umeclidinium/Vilanterol): First Dual Long-Acting Inhaler for Long-Term Maintenance Treatment of COPD
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Gazyva (Obinutuzumab) for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Gilotrif (Afatinib): Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Imbruvica (Ibrutinib) for Mantle-Cell Lymphoma: First Bruton’s Tyrosine Kinase Inhibitor Approved for Use in a Hematologic Malignancy
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Otrexup (Methotrexate) Injection: Novel Methotrexate Delivery System for Patients with Rheumatoid Arthritis
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Revlimid (Lenalidomide) Receives a New Indication for the Treatment of Patients with Relapsed or Progressing Mantle-Cell Lymphoma
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Tafinlar (Da­brafenib) and Mekinist (Trametinib): Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7 in Payers' Guide
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Lisa A. Raedler, PhD, RPh
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Drug Updates
Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
Lisa A. Raedler, PhD, RPh
Web Exclusives in FDA Approvals, Select Drug Profiles
New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib Therapy from ASCO 2013 and EHA 2013
Lisa A. Raedler, PhD, RPh
Supplements
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
August 2013 Vol 6, No 6 Special Issue in Drug Updates
Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
Lisa A. Raedler, PhD, RPh
Web Exclusives in FDA Approvals, Select Drug Profiles
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
Lisa A. Raedler, PhD, RPh
Web Exclusives in FDA Approvals, Select Drug Profiles
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
Web Exclusives in FDA Approvals, Select Drug Profiles
Last modified: October 7, 2016
SUBSCRIBE
Copyright © Amplity Medical Communications. All rights reserved.